Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II open-label study of single agent imetelstat in patients with essential
thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one
prior therapy, or who refuse standard therapy.